ArticleThyroid research2025
High Ki-67 labeling index correlates with aggressive clinicopathological features in papillary thyroid carcinoma: a retrospective study.
Article in Thyroid research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Article
- The Role of Cytology, Histology and Molecular Pathology in the Diagnostic Process of Thyroid Nodules.Cancers · 2026Review
- Machine Learning in Biomarker-Driven Precision Oncology: Automated Immunohistochemistry Scoring and Emerging Directions in Genitourinary Cancers.Current oncology (Toronto, Ont.) · 2026Review
- Ultrasound radiomics for preoperative evaluation of Ki-67 proliferation index in papillary thyroid carcinoma.Frontiers in oncology · 2026Article
- Modulation of oxidative stress and metabolic burden in papillary thyroid cancer by SGLT2 and broad DPP inhibition.Frontiers in molecular biosciences · 2026Article
- Clinicopathological, proliferative, molecular, and prognostic characteristics of differentiated high-grade thyroid carcinoma: a multicenter retrospective study.Frontiers in oncology · 2026Article
- Neuroendocrine Neoplasms of the Gastrointestinal Tract: Morphology, WHO 2022 Grading, and Prognostic Perspectives.Cureus · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPapillary thyroid carcinoma (PTC) is the most prevalent thyroid carcinoma that possesses a wide range of biological behavior. Various clinical and histopathological features, including BRAFV600E profile, are used to stratify the risk of disease recurrence in thyroid carcinoma. Recent studies have taken an interest in the potential of the proliferation index, Ki-67, in predicting the aggressive nature of PTC.
methodsThis is a single-center, retrospective study that included 92 PTC cases diagnosed at the Department of Anatomical Pathology, Faculty of Medicine/Dr. Cipto Mangunkusumo Hospital, from January 2019-December 2022. Continuous and categorical analysis of Ki-67 labeling index (LI) was studied and compared with various clinicopathological features and BRAFV6000E status.
resultsKi-67 LI was identified in PTCs (range = 0.1–17.1%, median = 2.45%). Higher Ki-67 LI (median value and Ki-67 LI > 5%) is significantly correlated with older age, advanced stage, lymph node metastasis, distant/organ metastasis, aggressive histological subtypes, unencapsulated tumors, lymphovascular invasion, extrathyroidal extension, and BRAFV600E mutation.
conclusionThe proliferation activity shown by Ki-67 LI correlates with aggressive tumor characteristics and may imply possible prognostic significance in diagnosing PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.